Home News

Financial Results Nine month period 2019 - Video

Javier López-Belmonte, Vicepresident and CFO of Laboratorios Farmacéuticos ROVI presents the financial results for the first nine months of 2019.

Mon, 25/11/2019 - 11:12 0 min
Download related document
No votes yet
 
Related
ROVI reports operating revenue growth of 10%, underpinned by the behaviour of...
The operating revenue of Laboratorios Farmacéuticos ROVI increased by 10% to 303.2 million euros in 2018, driven mainly by the strength of...
5 min
26/02/2019
ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French...
Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has reached an agreement with a subsidiary of MSD (“MSD”) whereby ROVI acquires certain...
2 min
15/02/2019
ROVI acquires Falithrom® for the German market
Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has announced the purchase of Falithrom®, which was owned by Hexal AG (“Hexal”), a company...
1 min
09/01/2019